📈MEMX Rule Change Notice for Improved Compliance and Clarity
The Securities and Exchange Commission publishes MEMX LLC's proposed rule change aimed at correcting non-substantive errors in their rulebook. The changes include updates to typographical errors, cross-references, and outdated citations to provide greater accuracy and clarity, ultimately serving to protect investors and enhance the trustworthiness of the exchange's operations.
Learn More⚡Overview of Electric Rate Filings and Securities Authorization
The document outlines multiple filings regarding electric rates and securities, including market-based rate applications effective in 2025. It specifies the responsible agencies, applicants, and important dates for comment and compliance, amidst a clear call for public engagement in the regulatory process.
Learn More🧬FDA Classifies Pharmacogenetic Assessment System as Class II Device
The Food and Drug Administration (FDA, the Agency, or we) is classifying the pharmacogenetic assessment system into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the pharmacogenetic assessment system. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
Learn More📈SEC Extends Review Period for 21Shares Ethereum ETF Rule Change
The SEC has designated an extended review period for Cboe BZX Exchange's proposed rule change to list and trade shares of the 21Shares Core Ethereum ETF. This proposed amendment aims to allow staking under specific rules, reflecting the evolving landscape of cryptocurrency regulations and the need for careful consideration of its implications.
Learn More⚠️NRC Decision on Holtec's Use of Decommissioning Trust Funds
The U.S. Nuclear Regulatory Commission (NRC) has issued a director's decision with regard to a petition dated December 5, 2023, as supplemented by public meeting transcript dated April 10, 2024, filed by Beyond Nuclear, Michigan Safe Energy Future, and Don't Waste Michigan (the petitioner), requesting that the NRC take action with regard to Holtec Palisades, LLC and Holtec Decommissioning International, LLC (the licensee). The petitioner's requests and the director's decision are included in the SUPPLEMENTARY INFORMATION section of this document.
Learn More🏗️Notice on Seismic Safety Requirements for New Building Construction
In accordance with the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35, as amended), the United States Department of Agriculture (USDA) Rural Utilities Service (RUS) announces its' intention to request an extension of a currently approved information collection and invites comments on this information collection.
Learn More📄USPTO Seeks Comments on Invention Promoters Complaint Process
The United States Patent and Trademark Office (USPTO) will submit the following information collection request to the Office of Management and Budget (OMB) for review and clearance in accordance with the Paperwork Reduction Act of 1995, on or after the date of publication of this notice. The USPTO invites comments on this information collection renewal of 0651-0044 (Complaints Regarding Invention Promoters), which helps the USPTO assess the impact of its information collection requirements and minimize the public's reporting burden. Public comments were previously requested via the Federal Register on May 19, 2025, during a 60-day comment period (90 FR 21295) This notice allows for an additional 30 days for public comment.
Learn More⚡Notice of Natural Gas Pipeline Rate Regulatory Filings
The Department of Energy, through the Federal Energy Regulatory Commission, has issued a notice regarding pending rate and refund filings from Tidal Energy Marketing and Cannat Energy Inc. The notice includes details on dockets, comment deadlines, and filing requirements for parties interested in intervening in the proceedings, emphasizing public engagement and compliance with regulatory process.
Learn More🦠FDA Classifies Multiplex Respiratory Panel for Respiratory Pathogens
The Food and Drug Administration (FDA, the Agency, or we) is classifying the multiplex respiratory panel to detect and identify emerging respiratory pathogen(s) and common respiratory pathogens in human clinical specimens into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the multiplex respiratory panel to detect and identify emerging respiratory pathogen(s) and common respiratory pathogens in human clinical specimens. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
Learn More🏥HIPAA Modifications
This document updates compliance and other dates presented in the final rule that appeared in the December 13, 2024 Federal Register titled "Administrative Simplification: Modifications of Health Insurance Portability and Accountability Act of 1996 (HIPAA) National Council for Prescription Drug Programs (NCPDP) Retail Pharmacy Standards; and Modification of the Medicaid Pharmacy Subrogation Standard" to conform with the subsequent final rule that appeared in the February 11, 2025 Federal Register.
Learn More